The University of Chicago Header Logo

Connection

Michael Charlton to Antiviral Agents

Back to Details
This is a "connection" page, showing publications Michael Charlton has written about Antiviral Agents.
Michael Charlton
Connection Strength
7.550
Antiviral Agents
  1. Liver Transplantation of HCV-viremic Donors Into HCV-negative Recipients in the United States: Increasing Frequency With Profound Geographic Variation. Transplantation. 2021 06 01; 105(6):1285-1290.
    View in: PubMed
    Score: 0.596
  2. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020 Sep; 55(9):811-823.
    View in: PubMed
    Score: 0.560
  3. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation. 2019 04; 103(4):733-746.
    View in: PubMed
    Score: 0.512
  4. Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med. 2016 04 28; 374(17):1688.
    View in: PubMed
    Score: 0.418
  5. Response to Fibrosis progression in patients treated for hepatitis C recurrence. Liver Int. 2015 Dec; 35(12):2625.
    View in: PubMed
    Score: 0.407
  6. A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016 Feb; 63(2):634-43.
    View in: PubMed
    Score: 0.401
  7. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
    View in: PubMed
    Score: 0.395
  8. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
    View in: PubMed
    Score: 0.392
  9. Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful? Liver Int. 2015 Jan; 35(1):9-11.
    View in: PubMed
    Score: 0.382
  10. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
    View in: PubMed
    Score: 0.376
  11. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail. Hepatology. 2011 Jul; 54(1):3-5.
    View in: PubMed
    Score: 0.299
  12. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant. 2009 Aug; 9(8):1707-13.
    View in: PubMed
    Score: 0.260
  13. Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep. 2007 Mar; 9(1):23-30.
    View in: PubMed
    Score: 0.222
  14. Pre-emptive treatment of recurrent hepatitis C infection. Liver Transpl. 2002 Oct; 8(10 Suppl 1):S50-4.
    View in: PubMed
    Score: 0.163
  15. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl. 2002 Jul; 8(7):623-9.
    View in: PubMed
    Score: 0.160
  16. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002 Apr; 8(4):350-5.
    View in: PubMed
    Score: 0.158
  17. Improved Graft Survival After Liver Transplantation for Recipients With Hepatitis C Virus in the Direct-Acting Antiviral Era. Liver Transpl. 2019 04; 25(4):598-609.
    View in: PubMed
    Score: 0.128
  18. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology. 2018 06; 154(8):2111-2121.e8.
    View in: PubMed
    Score: 0.119
  19. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017 05; 101(5):945-955.
    View in: PubMed
    Score: 0.112
  20. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. Transplantation. 2017 05; 101(5):956-967.
    View in: PubMed
    Score: 0.112
  21. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 03; 15(3):421-430.e6.
    View in: PubMed
    Score: 0.109
  22. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016 10; 1(2):122-132.
    View in: PubMed
    Score: 0.107
  23. Hepatitis C Virus RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen. Gastroenterology. 2016 10; 151(4):633-636.e3.
    View in: PubMed
    Score: 0.106
  24. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6):541-546.
    View in: PubMed
    Score: 0.103
  25. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
    View in: PubMed
    Score: 0.101
  26. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015 May; 61(5):1485-94.
    View in: PubMed
    Score: 0.097
  27. Comparative effectiveness of telaprevir-based triple therapy in patients with chronic hepatitis C. Mayo Clin Proc. 2014 May; 89(5):595-601.
    View in: PubMed
    Score: 0.090
  28. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl. 2013 Aug; 19(8):887-95.
    View in: PubMed
    Score: 0.087
  29. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19(7):690-700.
    View in: PubMed
    Score: 0.086
  30. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol. 2010 Sep; 44(8):e178-85.
    View in: PubMed
    Score: 0.071
  31. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008 Nov; 8(11):2426-33.
    View in: PubMed
    Score: 0.061
  32. Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006 Jun; 43(6):1177-86.
    View in: PubMed
    Score: 0.053
  33. Recurrence of hepatitis C infection: Where are we now? Liver Transpl. 2005 Nov; (11 Suppl 2):S57-62.
    View in: PubMed
    Score: 0.051
  34. Management of recurrence of hepatitis C infection following liver transplantation. Minerva Chir. 2003 Oct; 58(5):717-24.
    View in: PubMed
    Score: 0.044
  35. Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
    View in: PubMed
    Score: 0.044
  36. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis. 2003 Aug; 7(3):585-602.
    View in: PubMed
    Score: 0.043
  37. Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors. Hepatology. 2019 06; 69(6):2381-2395.
    View in: PubMed
    Score: 0.032
  38. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017 10; 24(10):823-831.
    View in: PubMed
    Score: 0.028
  39. Introduction to the genetics and biology of interleukin-28B. Hepatology. 2012 Jul; 56(1):361-6.
    View in: PubMed
    Score: 0.020
  40. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
    View in: PubMed
    Score: 0.019
  41. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May; 17(5):528-38.
    View in: PubMed
    Score: 0.018
  42. The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Apr; 94(4):1000-5.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.